Lonza to invest $7.95m in Meta metaldehyde formulation plant
Lonza is set to invest around $7.95m in a Meta metaldehyde formulation plant to supply metaldehyde as an active substance and with ready-made slug pellets.
GlaxoSmithKline PLC says it has signed an agreement with Lonza for the Swiss company to manufacture a number of drug compounds.